Pyxis Oncology will participate in three September 2026 investor conferences, where Interim CEO Tom Civik will discuss the company's pipeline and MICVO program. Updated Phase 1 monotherapy data in recurrent/metastatic head and neck cancer are expected in fall 2026, followed by Phase 1/2 combination data with KEYTRUDA in Q4 2026.
The biotech sector has always been a space where science, capital, and sentiment intersect in complex ways. From cautious optimism around breakthrough therapies to concerns over valuation and funding cycles, analyst perspectives continue to offer critical signals about where the industry may be headed...
Pyxis Oncology, Inc. (PYXS), a clinical-stage company, reported financial results for the full year 2025, reflecting an expanded net loss and provided near-term milestones for its lead investigational candidate, MICVO, for the treatment of solid tumours. Following the news, PYXS is trading at $1.43,...
Pyxis Oncology Inc. (PYXS) has emerged as a clinical-stage biopharmaceutical company to watch, with a clear focus on developing innovative therapeutics for difficult-to-treat cancers. Its lead candidate, micvotabart pelidotin (MICVO), represents a first-in-concept antibody drug conjugate (ADC) targeting...
Pyxis Oncology, Inc. (PYXS) reported Loss for full year of -$77.33 million The company's bottom line came in at -$77.33 million, or -$1.32 per share. This compares with -$73.79 million, or -$1.85 per share, last year. Pyxis Oncology, Inc. earnings at a glance (GAAP) : -Earnings: -$77.33 Mln....
August 13, 2026 05:33 ET The World Health Organization’s cancer research agency, the International Agency for Research on Cancer (IARC), has classified three widely used medicines as carcinogenic to humans.